Fulcrum Therapeutics (FULC) Shares Outstanding (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Shares Outstanding (Entity) of $76.3 million for Q2 2026, up 41.05% year-over-year from $54.1 million in Q2 2025, and up 14.55% quarter-over-quarter from $66.6 million in Q1 2026.
Fulcrum Therapeutics (FULC) Shares Outstanding (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Shares Outstanding (Entity) for 9 consecutive years, with $76.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 41.05% year-over-year to $76.3 million; the TTM figure through Jun 2026 stood at $76.3 million (up 41.05% YoY), while the FY2025 annual figure was $63355.0, up 2.21% from the prior year.
- Shares Outstanding (Entity) grew to $76.3 million in Q2 2026 per FULC's latest filing, from $66.6 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $76.3 million in Q2 2026 and bottomed at $40890.0 in Q2 2022.
- Historically, Shares Outstanding (Entity) has averaged $25.7 million across 5 years, with a median of $62669.5 in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 129013.31% — and 2023, when it tumbled 99.85%.
- Fulcrum Therapeutics' Shares Outstanding (Entity) stood at $44991.0 in 2022, then soared by 36.27% to $61310.0 in 2023, then climbed by 1.1% to $61984.0 in 2024, then increased by 2.21% to $63355.0 in 2025, then jumped by 120328.15% to $76.3 million in 2026.
- Business Quant data shows FULC's Shares Outstanding (Entity) at $76.3 million in Q2 2026, $66.6 million in Q1 2026, and $63355.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | 76.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.26 Mn |
| Mar 31, 2026 | 76.22 Mn |
| Dec 31, 2025 | 63,355.00 |
| Sep 30, 2025 | 62.60 Mn |
| Jun 30, 2025 | 62.54 Mn |
| Mar 31, 2025 | 62.48 Mn |
| Dec 31, 2024 | 61,984.00 |
| Sep 30, 2024 | 62.41 Mn |
| Jun 30, 2024 | 62.21 Mn |
| Mar 31, 2024 | 61,984.00 |
| Dec 31, 2023 | 61,310.00 |
| Sep 30, 2023 | 61,823.00 |
| Jun 30, 2023 | 61,794.00 |
| Mar 31, 2023 | 59,722.00 |
| Dec 31, 2022 | 44,991.00 |
| Sep 30, 2022 | 46,213.00 |
| Jun 30, 2022 | 40,890.00 |
| Mar 31, 2022 | 40.64 Mn |
| Dec 31, 2021 | 35,361.00 |
| Sep 30, 2021 | 36,606.00 |